Iveda Announces Pricing of $2 Million Public Offering

Rhea-AI Summary

Iveda (Nasdaq: IVDA) priced a public offering of 5,714,286 common shares (or pre-funded warrants) plus series X warrants to buy up to 11,428,572 shares at a combined public offering price of $0.35 per share with accompanying warrants.

The series X warrants are exercisable immediately, expire in two years, and the offering is expected to close on or about February 11, 2026, with gross proceeds of approximately $2.0 million before fees. The registration statement was declared effective on February 9, 2026.

Positive

• Gross proceeds of approximately $2.0 million
• Proceeds available for general corporate purposes
• Series X warrants exercisable immediately

Negative

• Issuance of shares and warrants may cause shareholder dilution
• Offering priced at $0.35 per share could pressure market valuation
• Net proceeds reduced by placement agent fees and offering expenses

Market Reaction

-35.57% $0.24 16.0x vol

15m delay 7 alerts

-35.57% Since News

-5.5% Trough in 4 hr 52 min

$0.24 Last Price

$0.23 $0.26 Day Range

-$788K Valuation Impact

$1M Market Cap

16.0x Rel. Volume

Following this news, IVDA has declined 35.57%, reflecting a significant negative market reaction. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.24. This price movement has removed approximately $788K from the company's valuation. Trading volume is exceptionally heavy at 16.0x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Offering size: $2.0 million Shares offered: 5,714,286 shares Series X warrant shares: 11,428,572 shares +5 more

8 metrics

Offering size $2.0 million Gross proceeds from Feb 2026 public offering before fees

Shares offered 5,714,286 shares Common stock or pre-funded warrants in Feb 2026 offering

Series X warrant shares 11,428,572 shares Common stock issuable upon exercise of Feb 2026 Series X warrants

Offering price $0.35 per share Combined public offering price for share (or pre-funded warrant) plus Series X warrant

Warrant exercise price $0.35 per share Exercise price of Series X warrants, exercisable immediately for two years

Price change 24h -17.51% Move prior to/into Feb 9, 2026 offering announcement

Prior offering size $2.15 million Registered direct offering announced Sep 5, 2024

Warrant cash potential $4.4 million Maximum cash IVDA would receive if all registered warrants are exercised

Market Reality Check

Price: $0.3770 Vol: Volume 1,561,022 is 4.29x...

high vol

$0.3770 Last Close

Volume Volume 1,561,022 is 4.29x the 20-day average of 363,591, indicating heavy trading into the offering news. high

Technical Shares trade below the 200-day MA of 1.54, with a pre-news price of 0.377, and sit close to the 52-week low of 0.357 and far below the 3.55 high.

Peers on Argus

IVDA fell 17.51% while peers showed mixed moves: BKYI +1.68%, VRME +3.81%, SPCB ...

IVDA fell 17.51% while peers showed mixed moves: BKYI +1.68%, VRME +3.81%, SPCB +1.14%, versus SUGP -3.21% and GFAI -9.65%, pointing to stock-specific dilution rather than a sector-wide move.

Previous Offering Reports

1 past event · Latest: Sep 05 (Negative)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Sep 05	Equity offering	Negative	-25.6%	Registered direct equity raise with shares and warrants priced at-the-market.

Pattern Detected

Prior equity offerings for IVDA have coincided with sharp negative reactions, with the last tagged offering moving the stock -25.62% the following day.

Recent Company History

The most relevant history for this offering is IVDA’s September 5, 2024 registered direct deal, where the company raised $2.15 million by issuing 5,000,000 shares (or pre-funded warrants) at $0.43, plus Series A and B warrants for up to 10,000,000 additional shares. That financing, arranged through H.C. Wainwright and linked to a shelf registration, saw the stock fall 25.62% over the next 24 hours, suggesting a history of weak price responses to dilution events.

Historical Comparison

offering

-25.6 %

Average Historical Move

Historical Analysis

IVDA’s last tagged offering on Sep 5, 2024 raised $2.15M and led to a -25.62% move, underscoring a pattern of sharp selloffs around equity financings.

Typical Pattern

Recent financing history shows repeated capital raises using common stock, pre-funded warrants and series warrants under an existing shelf structure.

Regulatory & Risk Context

Active S-3 Shelf · $4.4 million

Shelf Active

Active S-3 Shelf Registration 2025-10-22

$4.4 million registered capacity

IVDA has an effective S-3 resale registration for up to 1,296,876 warrant shares at exercise prices of $3.44 and $4.30. The company would receive up to $4.4 million only if these warrants are exercised for cash; the filing itself involves selling stockholders and does not provide new primary proceeds.

Market Pulse Summary

The stock is dropping -35.6% following this news. The decline reflects a recurring pattern where IVD...

Analysis

The stock is dropping -35.6% following this news. The decline reflects a recurring pattern where IVDA traded lower on equity financings, similar to the -25.62% move after its $2.15M September 2024 offering. This deal adds 5,714,286 shares (or pre-funded warrants) plus 11,428,572 Series X warrant shares at $0.35, on top of an S-3-backed warrant overhang of up to 1,296,876 shares and potential $4.4M in warrant-funded dilution.

Key Terms

pre-funded warrants, series X warrants, public offering, registration statement on Form S-1, +2 more

6 terms

pre-funded warrants financial

"5,714,286 shares of its common stock (or pre-funded warrants in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

series X warrants financial

"and series X warrants to purchase up to 11,428,572 shares of its common stock"

Series X warrants are a specific class (or tranche) of warrants — financial instruments that give the holder the right, but not the obligation, to buy a set number of a company's shares at a predetermined price before a fixed expiry date. They matter to investors because exercising them can dilute existing shareholdings and signal potential future capital raising, while offering holders leveraged upside if the stock rises above the strike price, similar to a coupon that lets you buy a concert ticket at today’s price even if ticket prices climb later.

public offering financial

"today announced the pricing of a public offering of 5,714,286 shares"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

registration statement on Form S-1 regulatory

"A registration statement on Form S-1 (File No. 333-293126) relating to the public offering"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The public offering is being made only by means of a prospectus forming part of the effective registration"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

Securities and Exchange Commission regulatory

"declared effective by the Securities and Exchange Commission (the “SEC”) on February 9, 2026"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

AI-generated analysis. Not financial advice.

MESA, Ariz., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Iveda^® (Nasdaq: IVDA), the global leader in AI video surveillance and smart city solutions, today announced the pricing of a public offering of 5,714,286 shares of its common stock (or pre-funded warrants in lieu thereof) and series X warrants to purchase up to 11,428,572 shares of its common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying series X warrants. The series X warrants will have an exercise price of $0.35 per share, will be exercisable immediately upon issuance and will expire two years from the date of issuance. The closing of the offering is expected to occur on or about February 11, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering are expected to be approximately $2.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include research and development, repayment of existing indebtedness, working capital, capital expenditures, acquisitions, joint ventures and stock repurchase programs.

A registration statement on Form S-1 (File No. 333-293126) relating to the public offering was declared effective by the Securities and Exchange Commission (the “SEC”) on February 9, 2026. The public offering is being made only by means of a prospectus forming part of the effective registration statement relating to the public offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Iveda Solutions^®

Iveda (NASDAQ: IVDA) is the provider of global solutions for cloud-based, video AI search and surveillance technologies that protect the people, places, and things that matter the most. Iveda’s technology provides instant intelligence to existing infrastructure, enabling cities and organizations around the world to seamlessly enter the fifth industrial revolution. Headquartered in Mesa, Arizona, with a subsidiary in Taiwan, Iveda is publicly traded under the ticker symbol “IVDA.”

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including, without limitation, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. These statements are based on current expectations as of the date of this press release and involve risks and uncertainties that may cause results and uses of proceeds to differ materially from those indicated by these forward-looking statements. We encourage readers to review the “Risk Factors” in the prospectus included in our registration statement on Form S-1 for a comprehensive understanding. Iveda undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable laws or regulations.

Media Contact

Olivia Civiletto Erwin
olivia@dottedlinecomm.com
716.785.1108

FAQ

What did Iveda (IVDA) announce about its February 2026 public offering?

Iveda priced a public offering of 5,714,286 shares plus series X warrants exercisable for 11,428,572 shares. According to the company, the combined public offering price is $0.35 per share and gross proceeds are expected to be about $2.0 million before fees.

When will the Iveda (IVDA) offering close and when was its registration declared effective?

The offering is expected to close on or about February 11, 2026. According to the company, the registration statement for the offering was declared effective by the SEC on February 9, 2026.

What are the terms of the series X warrants issued in the Iveda (IVDA) offering?

Series X warrants have a $0.35 exercise price and expire two years from issuance. According to the company, the warrants are exercisable immediately upon issuance and accompany each share sold in the offering.

How does Iveda (IVDA) intend to use the net proceeds from the $2.0M offering?

Iveda intends to use net proceeds for general corporate purposes, including R&D and debt repayment. According to the company, uses may also include working capital, capital expenditures, acquisitions, joint ventures, and stock repurchases.

Who is managing the Iveda (IVDA) public offering and where can investors find the prospectus?

H.C. Wainwright & Co. is the exclusive placement agent for the offering. According to the company, the final prospectus will be available on the SEC website and from H.C. Wainwright when available.